David Gardner called it. He?s up 1,334%! See what David?s recommending that you buy NEXT. Click Here Now Investors are always hunting for the next big stock -- the dream stock whose price increases several times over when the market finally discovers it. It's easy to look back and discover the 10 best stocks of the past decade. But I'm more interested in the tools that can help me evaluate tomorrow's greatest companies.
Motley Fool CAPS offers a variety of resources to aid Fools in finding tomorrow's leaders. Our 150,000-member community is full of investors helping each other beat the market.
We'll enlist CAPS to screen for biotech companies, then get the story behind some of its more highly rated stocks. CAPS' nifty screener will help us find stocks with:
A market cap of at least $100 million. A three-year revenue growth rate of at least 30%. A price-to-earnings ratio of less than 25. Then we'll tap the collective intelligence of our CAPS members to see whether these companies present real opportunities -- or whether the numbers fail to tell the true story.
Opinions with the numbers Here are some of the more interesting stocks our screen returned.
Company Revenue Growth Rate, Past 3 Years CAPS Rating (out of 5) Keryx Biopharmaceuticals (Nasdaq: KERX) 158.5% *** VIVUS (Nasdaq: VVUS) 64.6% *** Biogen Idec (Nasdaq: BIIB) 35.6% *** Data and star rankings from CAPS as of Feb. 11. Keryx Biopharmaceuticals Keryx has shown good progress with its drug candidates in clinical trials recently, especially the news that its colon cancer drug, perifosine, showed a more than 60% improvement in overall survival in midstage trials. The company looks to begin late-stage trials in the second quarter, and is also working on other treatments for the drug that show promise. Top all this off with other expected late-stage trials for its kidney drug, Zerenex, and it's no wonder a solid following of CAPS investors see potentially brighter days ahead for the company.
At this point, about 91% of the 209 CAPS members rating Keryx Biopharmaceuticals see it outperforming the broader market.
March 1, 2010 7:42 AM EST Aterna Zentaris Inc. (NASDAQ: AEZS) has received a positive opinion for orphan medicinal product designation for its compound perifosine from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of multiple myeloma. Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), Aterna Zentaris' partner and licensee for perifosine in the North American market, already announced in September 2009 that it has received Orphan Drug Designation for perifosine for the treatment of multiple myeloma from the U.S. Food and Drug Administration (FDA).
Orphan medicinal product designation is granted by the European Commission, following a positive opinion from the COMP, to a medicinal product that is intended for the diagnosis, prevention or treatment of a life-threatening or a chronically debilitating condition affecting not more than five in 10,000 persons in the Community when the application for designation is submitted.